Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
Eppendorf is proud to announce the launch of its D
The Nobel Prize in Physiology or Medicine awarded
This year, the Hamburg based life sciences company
Alembic Pharmaceuticals Ltd., t
Since it’s an ingredient in so many foods, you h
Dear Readers, Welcome to the latest issue of Micr
Combining AstraZeneca’s COVID-19 vaccine with a second dose from either Pfizer-BioNTech or Moderna’s jab provides “good protection”, Denmark’s State Serum Institute said on Monday.
A growing number of countries are looking at switching to different COVID-19 vaccines for second doses, a measure particularly necessary in Denmark after health authorities discontinued inoculations with AstraZeneca’s vaccine in April over rare side-effect concerns.
“The study shows that fourteen days after a combined vaccination program, the risk of infection with SARS-CoV-2 is reduced by 88% compared to unvaccinated individuals,” the State Serum Institute (SSI) said.
That is a “high efficacy”, SSI added, comparable to the 90% efficacy rate of two doses from Pfizer-BioNTech’s vaccine, confirmed in a different Danish study.
It could not conclude whether the same protection applied to the Delta-variant, which is now the most widespread in Denmark.
It also provided no efficacy data on COVID-19 related deaths or hospitalisations, since none took place following the combined vaccination programme.
